Viewing Study NCT02907606


Ignite Creation Date: 2025-12-26 @ 4:03 PM
Ignite Modification Date: 2026-02-28 @ 8:18 AM
Study NCT ID: NCT02907606
Status: UNKNOWN
Last Update Posted: 2016-09-20
First Post: 2016-09-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
Sponsor: Peking University People's Hospital
Organization:

Study Overview

Official Title: Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
Status: UNKNOWN
Status Verified Date: 2016-09
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.
Detailed Description: Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring.

Urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. To date, only a limited number of published studies have examined the feasibility of ctDNA detection from urine.

This study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired samples.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: